Molecular classification of diffuse gliomas

ONCOLOGY (United States)

Volumn 27, Issue 6, 2013, Pages

  Olar, Adriana ^a   Prabhu, Sujit S ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE;

ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CORRELATIONAL STUDY; GENE; GENE MUTATION; GLIOMA; HISTOPATHOLOGY; HUMAN; IDH1 GENE; IDH2 GENE; MIXED OLIGOASTROCYTOMA; MIXED TUMOR; OLIGODENDROGLIOMA; PRACTICE GUIDELINE; TUMOR CLASSIFICATION;

EID: 84879818498     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumors of the central nervous system. 4th ed. Lyon (France): IARC; 2007.
2. Holdhoff M, Grossman SA. Controversies in the adjuvant therapy of high-grade gliomas. Oncologist. 2011;16:351-8.
3. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Central nervous system cancers. Version 2.2013. Available from: http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed May 21, 2013.
4. Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3:709-22.
5. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874-80.
6. Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology. 2009;73:1792-5.
7. Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol. 2012;109:15-22.
8. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120:707-18.
9. Metellus P, Coulibaly B, Colin C, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 2010;120:719-29.
10. Ellezam B, Theeler BJ, Walbert T, et al. Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas. Acta Neuropathol. 2012;124:449-51.
11. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med. 2007;131:242-51.
12. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-9.
13. Cairncross G, Jenkins R. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J. 2008;14:352-7.
14. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68:1831-6.
15. Capper D, Reuss D, Schittenhelm J, et al. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol. 2011;121:241-52.
16. Olar A, Fuller GN. Molecular diagnosis of glioma. In: Tan D, Lynch H (editors). Principles of molecular diagnostics and personalized cancer medicine. Baltimore, Md: Lippincott Williams & Wilkins/Wolters Kluwer Health, 2013;520-7.